نتایج جستجو برای: ibritumomab tiuxetan
تعداد نتایج: 246 فیلتر نتایج به سال:
Purpose: Radioimmunotherapy has been approved for relapsed follicular lymphoma (FL), including rituximab-refractory FL. This study was designed to determine the CR rate with shortcourse chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) followed by 90-Y ibritumomab tiuxetan (RIT) with extended rituximab as first-line treatment. Experimental De...
Radioimmunotherapy (RIT) combines the use of targeted monoclonal antibodies with radionuclides for the treatment of non-Hodgkin's lymphoma (NHL), taking advantage of its inherent radiosensitivity. A number of trials have shown significantly higher response rates and longer progression-free survival times in patients treated with the CD20-targeted radioimmunoconjugate yttrium-90-ibritumomab tiux...
technology which captures the fluorescence emitted from the gastrointestinal tract. AFI has been reported to improve the detection rate of epithelial neoplasms in the colon [1] and be useful for differential diagnosis of gastrointestinal tract lymphoma lesions [2]. We have recently encountered a case of lymphoma inwhich recurrent lesions were clearly detected by AFI at quite an early stage. A 6...
Introduction: Patients (pts) with follicular lymphoma (FL) can have long survival, nevertheless most of them subsequent relapses disease-free intervals progressively shorter. In the present chemo-free era role transplantation has been questioned and its right place in treatment plan relapse/refractory (R/R) disease is still challenging. The aim this analysis was to collect long-term follow-up d...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید